Tariquidar (dihydrochloride)
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) [1].
Product Specifications
CAS Number
1992047-62-7
Product Name Alternative
XR9576 (dihydrochloride)
UNSPSC
12352005
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tariquidar-dihydrochloride.html
Solubility
10 mM in DMSO
Smiles
[H]Cl.[H]Cl.O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O
Molecular Formula
C38H40Cl2N4O6
Molecular Weight
719.65
References & Citations
[1]Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128 (2), 403-411.|[2]Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61 (2), 749-758.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Citation 01
J Control Release. 2022 Feb:342:44-52.|ACS Chem Neurosci. 2025 Sep 3;16 (17) :3340-3353.|Antimicrob Agents Chemother. 2015 Nov 30;60 (2) :946-54. |Antioxidants (Basel) . 2021 Jun 11;10 (6) :949.|Antiviral Res. 2021 Sep:193:105124.|bioRxiv. 2025 Jun 24:2025.06.18.660465.|bioRxiv. 2025 Sep 20.|Cell Death Discov. 2021 Aug 5;7 (1) :204.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|Commun Chem. 2024 Jul 13;7 (1) :158.|Crit Rev Anal Chem. 2022;52 (7) :1557-1571.|Eur J Drug Metab Pharmacokinet. 2018 Oct;43 (5) :599-606.|Eur J Med Chem. 2017 Feb 15:127:586-598.|Eur J Med Chem. 2018 Mar 10:147:7-20.|Eur J Pharm Sci. 2019 Jan 15:127:319-329.|Eur J Pharmacol. 2024 Apr 15:969:176431.|Hepatol Commun. 2024 May 2;8 (5) :e0437.|Int J Mol Sci. 2022 Nov 29;23 (23) :14948.|Int J Mol Sci. 2023 Mar 10;24 (6) :5298.|J Biomed Nanotechnol. 2018 Oct 1;14 (10) :1705-1718.|J Cereb Blood Flow Metab. 2016 Aug;36 (8) :1412-23. |J Cereb Blood Flow Metab. 2021 Jul;41 (7) :1634-1646.|J Control Release. 2022 Sep:349:109-117.|J Drug Deliv Sci Technol. May 2022, 103323.|J Nanopart Res. (2018) 20:176.|J Nat Prod. 2022 Dec 23;85 (12) :2746-2752.|Langmuir. 2015 May 12;31 (18) :5115-22. |Mar Drugs. 2022 Nov 25;20 (12) :738.|Mar Drugs. 2022 Sep 23;20 (10) :597.|Mar Drugs. 2023 Jan 14;21 (1) :54.|Mar Drugs. 2023 Mar 14;21 (3) :178.|Mar Drugs. 2024 Aug 30;22 (9) :396.|Mol Pharm. 2019 Mar 4;16 (3) :1282-1293.|Mol Pharm. 2021 Jan 4;18 (1) :416-428.|Pharm Res. 2017 Jan;34 (1) :148-160.|Pharmaceuticals (Basel) . 2023 Feb 24;16 (3) :349.|Pharmaceutics. 2021 Feb 26;13 (3) :306.|PLoS One. 2017 Sep 15;12 (9) :e0183662. |Res Sq. 2025 May 16.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2024 Feb 6.|Research Square Print. 2022 Jul.|RSC Adv. 2016,6, 69083-69093.|Sci Bull. 2016 Apr;61 (7) :552-560.|Sci Rep. 2017 Dec 22;7 (1) :18069.|Sci Rep. 2022 Aug 9;12 (1) :13570.|Small. 2020 Nov;16 (44) :e2004172.|Xenobiotica. 2020 Mar;50 (3) :354-362.|J Cereb Blood Flow Metab. 2020 Jan;40 (1) :150-162.|Mol Imaging Biol. 2019 Apr;21 (2) :257-268. |Mol Pharm. 2020 Sep 8;17 (9) :3477-3486.|Nucl Med Biol. 2018 May:60:29-36.|RWTH Aachen University. 2021 Oct.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS9926235 Inquire
Cavy Transmembrane Prolyl 4-Hydroxylase (P4HTM) ELISA Kit
Sign In for Pricing
View Details MBS6401113-01 0.1 mL
MAGEA1 (Melanoma-associated Antigen 1, MAGE-1 Antigen, Antigen MZ2-E, Cancer/Testis Antigen 1.1, CT1.1, MAGE1, MGC9326) (HRP)
Sign In for Pricing
View Details MBS6401113-02 5x 0.1 mL
MAGEA1 (Melanoma-associated Antigen 1, MAGE-1 Antigen, Antigen MZ2-E, Cancer/Testis Antigen 1.1, CT1.1, MAGE1, MGC9326) (HRP)
Sign In for Pricing
View Details 37271121 3x 1.0µg DNA
POU5F1P3 CRISPRa sgRNA lentivector (set of three targets)(Human)
Sign In for Pricing
View Details